NYSE:DGXHealthcare
Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test
Quest Diagnostics (NYSE:DGX) has partnered with Guardant Health to offer the FDA approved Shield blood test for colorectal cancer screening.
The agreement will make Shield available nationwide through Quest’s testing ecosystem, expanding access for patients and clinicians.
The collaboration focuses on a blood based option for colorectal cancer screening that may support broader adoption of preventive care.
For you as an investor, this move plugs directly into what Quest Diagnostics already...